Guggenheim Downgrades Immuneering to Neutral
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Michael Schmidt has downgraded Immuneering (NASDAQ:IMRX) from Buy to Neutral, indicating a change in the firm's outlook on the stock.

March 14, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Immuneering's stock rating was downgraded from Buy to Neutral by Guggenheim analyst Michael Schmidt.
Analyst ratings can significantly influence investor perception and stock price. A downgrade from 'Buy' to 'Neutral' suggests a less optimistic outlook on the stock's performance, potentially leading to a decrease in investor interest and a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100